Reaction equation
Cl[C:2]1[N:3]=[C:4]([N:23]2[CH2:28][CH2:27][O:26][CH2:25][CH2:24]2)[C:5]2[N:11]=[C:10]([CH2:12][N:13]3[CH2:18][CH2:17][CH:16]([C:19]([OH:22])([CH3:21])[CH3:20])[CH2:15][CH2:14]3)[CH:9]=[CH:8][C:6]=2[N:7]=1.[NH:29]1[C:33]2[CH:34]=[CH:35][CH:36]=[CH:37][C:32]=2[N:31]=[C:30]1[CH2:38][CH2:39][OH:40]>>[OH:40][CH2:39][CH2:38][C:30]1[N:29]([C:2]2[N:3]=[C:4]([N:23]3[CH2:24][CH2:25][O:26][CH2:27][CH2:28]3)[C:5]3[N:11]=[C:10]([CH2:12][N:13]4[CH2:14][CH2:15][CH:16]([C:19]([OH:22])([CH3:20])[CH3:21])[CH2:17][CH2:18]4)[CH:9]=[CH:8][C:6]=3[N:7]=2)[C:33]2[CH:34]=[CH:35][CH:36]=[CH:37][C:32]=2[N:31]=1Participants
3
Reactant 2
Product 1
Procedure
2-(1-((2-chloro-4-morpholinopyrido[3,2-d]pyrimidin-6-yl)methyl)piperidin-4-yl)propan-2-ol from Example 8 (0.15 g) was reacted with 2-(1H-benzo[d]imidazol-2-yl)ethanol via General Procedure D to produce 19 mg of 168 following reverse phase HPLC purification. MS (Q1) 532.3 (M)+
Workup
- customto produce
- custom19 mg of 168 following reverse phase HPLC purification
Sources & evidence
- ORD record
- ord-3a67ed27f0a54e51b8f7943c9ff90985
- Source dataset
- uspto-grants-2013_10
- Patent number
- US08563540B2
Linked notes
Loading…